Aurcana Corp. (AUNFF: OTCQX International) | Aurcana

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aurcana Corp. (AUNFF: OTCQX International) | Aurcana Reports Voting Results of Annual and Special Meeting Marketwire

Aurcana Reports Voting Results of Annual and Special Meeting

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 9, 2014) - Aurcana Corporation ("Aurcana" or the "Company") (TSX VENTURE:AUN)(OTCQX:AUNFF) is pleased to announce the results of its Annual and Special Meeting of Shareholders ("ASM") held on June 5, 2014.

A total of 28,782,990 shares were represented at the ASM being 44.40% of the issued and outstanding common shares as of the record date for the ASM. Shareholders voted in favour of al resolutions and each of the five nominees proposed as directors were elected. Details of the results are as follows:

Nominee Votes For % For Votes % Withheld
      Withheld  
Lenic Rodriguez 17,995,184 94.39 1,070,508 5.61
Robert Tweedy 17,490,823 91.74 1,574,869 8.26
Kevin Drover 17,440,826 91.48 1,624,866 8.52
Adrian Aguirre 17,459,569 91.58 1,606,123 8.42
Jerry Blackwell 18,336,446 96.18 729,246 3.82

The Company's shareholders also approved the re-appointment of PriceWaterhouseCoopers Canada to serve as auditor of the Company for the ensuing year.

About Aurcana Corporation

Aurcana Corporation is a primary silver producing company with two properties: the La Negra Mine in Mexico and the Shafter Project in Texas, US. La Negra is currently mining and milling at 3,000 tonnes per day producing copper, silver-lead and zinc concentrates. Shafter is currently on care and maintenance pending improved metal prices.

ON BEHALF OF THE BOARD OF DIRECTORS OF AURCANA CORPORATION

Lenic Rodriguez, President & CEO

This news release contains certain forward-looking statements, including statements regarding forecast silver production, silver grades, recoveries, potential mineralization, exploration result, future plans and objectives of the Company and the business and anticipated financial performance of the Company. These statements are forward-looking statements that involve various risks and uncertainties. These forward-looking statements include, but are not limited to, statements with respect to mining and processing of mined ore, achieving projected recovery rates, anticipated production rates and mine life, operating efficiencies, costs and expenditures, changes in mineral resources and conversion of mineral resources to proven and probable reserves, and other information that is based on forecasts of future operational or financial results, estimates of amounts not yet determinable and assumptions of management.Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or does not expect", "is expected", anticipates" or "does not anticipate" "plans", "estimates" or "intends" or stating that certain actions, events or results " may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be "forward-looking statements". Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to materially differ from those reflected in the forward-looking statements.

Actual results may differ materially from results contemplated by the forward-looking statements. Important factors that could differ materially from the Company's expectations include, among others,risks related to international operations, unsuccessful exploration results, conclusions of economic evaluations and changes in project parameters as plans continue to be refined as well as changes in metal prices, changes in the availability of funding for mineral exploration and development, unanticipated changes in key management personnel and general economic conditions. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward-looking statements, oral or written, made by itself or on its behalf, except as required by applicable law. Accordingly, readers should not place undue reliance on forward- looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Aurcana Corporation
(604) 331-9333
(866) 532-9333
(604) 633-9179
www.aurcana.com

Gary Lindsey
Corporate Relations
(720)-273-6224
gary@strata-star.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Man Group PLC Highlights Its Strategic Disclosures on Tritax REIT

Updated Category News Views 148

Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...

Continue Reading
TalentLMS and Epignosis Lead the Way in GDPR Compliance

Updated Category News Views 720

TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...

Continue Reading
Zillow and Esusu Forge New Path to Boost Renters' Credit Scores

Updated Category News Views 283

Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...

Continue Reading
iCrowdNewswire Leverages DeepL for Enhanced Global Communication

Updated Category News Views 121

iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...

Continue Reading
Celebrating Excellence: Top Surgeons Recognized in Endocrine Care

Updated Category News Views 82

Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...

Continue Reading